Analysis for characteristics of genetic mutations among multi-drug resistant <i>Mycobacterium tuberculosis</i> (MDR-TB) isolates from Zhejiang Province

ZHAO Gang; JIA Qing-jun; WU Yi-fei; HUANG Yin-yan; TANG Lei-ming; ZENG Mei-chun

doi:10.16462/j.cnki.zhjbkz.2021.01.013

Volume 25 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(1): 66-71

ZHAO Gang, JIA Qing-jun, WU Yi-fei, HUANG Yin-yan, TANG Lei-ming, ZENG Mei-chun. Analysis for characteristics of genetic mutations among multi-drug resistant Mycobacterium tuberculosis (MDR-TB) isolates from Zhejiang Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(1): 66-71. doi: 10.16462/j.cnki.zhjbkz.2021.01.013

Citation:

ZHAO Gang, JIA Qing-jun, WU Yi-fei, HUANG Yin-yan, TANG Lei-ming, ZENG Mei-chun. Analysis for characteristics of genetic mutations among multi-drug resistant Mycobacterium tuberculosis (MDR-TB) isolates from Zhejiang Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(1): 66-71. doi: 10.16462/j.cnki.zhjbkz.2021.01.013

Citation:

PDF( 16894 KB)

Analysis for characteristics of genetic mutations among multi-drug resistant Mycobacterium tuberculosis (MDR-TB) isolates from Zhejiang Province

doi: 10.16462/j.cnki.zhjbkz.2021.01.013

1.
Institute for Tuberculosis Control and Prevention, Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China
2.
Department of Clinical Laboratory, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, China
3.
Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China

Funds:

Hangzhou Science and Technology Development Plan Project 20191203B140

Hangzhou Health Science and Technology Plan Project A20200788

More Information

Corresponding author: JIA Qing-jun, E-mail: qingjunjia@126.com
Received Date: 2019-12-24
Rev Recd Date: 2020-04-20
Publish Date: 2021-01-10

Abstract

Abstract

Objective To analyze the characteristics of genetic mutations associated with isoniazid (INH) and rifampicin (RIF)-resistant Mycobacterium tuberculosis (MDR-TB) isolates. Methods Culture positive sputum specimens from suspicious TB were subjected to species identification. Genomic DNAs of Mycobacterium tuberculosis complex (MTBC) were extracted. InhA, katG, and Rifampicin Resistance Determining Region (RRDR) of rpoB gene were amplified. Amplicons were performed with Sanger sequencing. Results A total of 3 317 TB were identified, including3 009 new treated, 308 retreated, and 84 MDR-TB, accounting for 2.53% (84/3 317). In INH resistant isolates, 47 had single-point mutation in katG (315 site) or inhA (-15 or -8 site), and 19 had both katG and inhA mutations. The coincidence rate of genotype with phenotype was 78.57% (66/84). The most frequent mutation was Ser315Thr (47.62%, 40/84). In RIF resistant isolates, 79 had mutations in rpoB (sites 511, 512, 513, 516, 522, 526 and 531), and 2 had mutations in 511/513 or 511/516. The most frequent mutation was Ser531Leu (58.33%, 49/84). The coincidence rate of genotype with phenotype was 96.43% (81/84). Conclusions Genetic mutations of inhA, katG and rpoB gene in Zhejiang are concentrated relatively on common gene sites, and Xpert MTB/RIF is still of high application value to screen MDR-TB in Zhejiang.
- Zhejiang,
- Tuberculosis,
- katG,
- rpoB,
- inhA,
- Genetic mutations

FullText(HTML)

References(25)

References

[1]	World Health Organization. Global tuberculosis report 2019 [EB/OL]. (2019-10-15) [2019-12-20]. https://www.who.int/publications-detail/global-tuberculosis-report-2019.
[2]	Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China [J]. N Engl J Med, 2012, 366(23):2161-2170. DOI: 10.1056/nejmoa1108789.
[3]	Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made [J]. Eur Respir J, 2015, 45(1):150-160. DOI: 10.1183/09031936.00101814.
[4]	Zenteno-Cuevas R, Cuevas-Cordoba B, Parissi-Crivelli A. RpoB, katG and inhA mutations in multi-drug resistant strains of Mycobacterium tuberculosis clinical isolates from southeast Mexico [J]. Enferm Infecc Microbiol Clin, 2019, 37(5):307-313. DOI: 10.1016/j.eimc.2018.09.002.
[5]	Alvarez-Uria G, Reddy R. Differences in rpoB, katG and inhA mutations between new and previously treated tuberculosis cases using the GenoType MTBDRplus assay [J]. Infect Genet Evol, 2018, 59:48-50. DOI: 10.1016/j.meegid.2018.01.022.
[6]	Isakova J, Sovkhozova N, Vinnikov D, et al. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic [J]. BMC Microbiol, 2018, 18(1):22. DOI: 10.1186/s12866-018-1168-x.
[7]	Zhao LL, Huang MX, Xiao TY, et al. Prevalence, risk and genetic characteristics of drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China [J]. Infect Drug Resist, 2019, 12:2457-2465. DOI: 10.2147/IDR.S209971.
[8]	Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update [J]. Tuber Lung Dis, 1998, 79(1):3-29. DOI: 10.1054/tuld.1998.0002.
[9]	Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance [J]. J Mol Biol, 1988, 202(1):45-58. DOI: 10.1016/0022-2836(88)90517-7.
[10]	Prim RI, Schorner MA, Senna SG, et al. Molecular profiling of drug resistant isolates of Mycobacterium tuberculosis in the state of Santa Catarina, southern Brazil [J]. Mem Inst Oswaldo Cruz, 2015, 110(5):618-623. DOI: 10.1590/0074-02760150100.
[11]	赵雁林, 逄宇.结核病实验室检验规程[M].北京: 人民卫生出版社, 2015: 1-260. Zhao YL, Peng Y. Laboratory test procedures for tuberculosis [M]. People's Medical Publishing House, 2015: 1-260.
[12]	Deggim-Messmer V, Bloemberg GV, Ritter C, et al. Diagnostic molecular Mycobacteriology in regions with low tuberculosis endemicity: combining real-time PCR assays for detection of multiple Mycobacterial pathogens with line probe assays for identification of resistance mutations [J]. EBioMedicine, 2016, 9:228-237. DOI: 10.1016/j.ebiom.2016.06.016.
[13]	Peng Y, Chen SH, Zhang L, et al. Multidrug-resistant tuberculosis burden among the new tuberculosis patients in Zhejiang Province: an observational study, 2009-2013 [J]. Chin Med J (Engl), 2017, 130(17):2021-2026. DOI: 10.4103/0366-6999.213413.
[14]	张靓, 董恒进, 郜琳, 等.居民就诊意愿与基层医疗服务能力研究——以浙江兰溪为例[J].卫生经济研究, 2016, (8):19-22. DOI: 10.14055/j.cnki.33-1056/f.20160802.013. Zhang L, Dong HJ, Gao L, et al. Studies on residents' willingness to seek care and the ability of primary medical service capacity: Take Lanxi in Zhejiang Province as an example [J]. Health Economics Research, 2016, (8):19-22. DOI: 10.14055/j.cnki.33-1056/f.20160802.013.
[15]	Seifert M, Catanzaro D, Catanzaro A, et al. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review [J]. PLoS One, 2015, 10(3):e0119628. DOI: 10.1371/journal.pone.0119628.
[16]	Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis [J]. Int J Tuberc Lung Dis, 2009, 13(12):1456-1466.
[17]	Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis [J]. Lancet Infect Dis, 2003, 3(1):13-21. DOI: 10.1016/s1473-3099(03)00483-3.
[18]	Huyen MN, Cobelens FG, Buu TN, et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes [J]. Antimicrob Agents Chemother, 2013, 57(8):3620-3626. DOI: 10.1128/AAC.00077-13.
[19]	Luo T, Zhao M, Li X, et al. Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China [J]. Antimicrob Agents Chemother, 2010, 54(3):1075-1081. DOI: 10.1128/AAC.00964-09.
[20]	Zhao LL, Chen Y, Chen ZN, et al. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China [J]. Antimicrob Agents Chemother, 2014, 58(6):3475-3480. DOI: 10.1128/AAC.02426-14.
[21]	Luo D, Chen Q, Xiong G, et al. Prevalence and molecular characterization of multidrug-resistant M. tuberculosis in Jiangxi province, China [J]. Sci Rep, 2019, 9(1):7315. DOI: 10.1038/s41598-019-43547-2.
[22]	Kigozi E, Kasule GW, Musisi K, et al. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda [J]. PLoS One, 2018, 13(5):e0198091. DOI: 10.1371/journal.pone.0198091.
[23]	Luna JF, Montero H, Sampieri CL, et al. Sequencing of the entire rpob gene and characterization of mutations in isolates of Mycobacterium tuberculosis circulating in an endemic tuberculosis setting [J]. J Glob Antimicrob Resist, 2019, 19:98-103. DOI: 10.1016/j.jgar.2019.03.001.
[24]	Tavanaee SA, Ashna H, Kaffash A, et al. Mutations of rpob gene associated with rifampin resistance among Mycobacterium tuberculosis isolated in tuberculosis regional reference laboratory in northeast of Iran during 2015-2016 [J]. Ethiop J Health Sci, 2018, 28(3):299-304. DOI: 10.4314/ejhs.v28i3.7.
[25]	Koch AV, Mizrahi, Warner DF. The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin [J]. Emerg Microbes Infect, 2014, 3(3):e17. DOI: 10.1038/emi.2014.17.